GTCR Completes Acquisition of European Generics Leader Zentiva from Advent

GTCR, a leading private equity firm, announced that it has closed the previously announced acquisition of Zentiva, a leading European generics pharmaceutical company, from Advent, a leading global private equity investor.

GTCR will partner with Zentiva's management team, led by Chief Executive Officer Steffen Saltofte and Executive Chairperson Kieran Murphy, to support the Company's next phase of growth. GTCR has longstanding relationships with both Mr. Saltofte and Mr. Murphy, both seasoned leaders with proven track records at various healthcare businesses, including at Acino and GE HealthCare.

"We are proud of Zentiva's strong history and footprint. We look forward to partnering with GTCR at an important inflection point following several years of growth," said Steffen Saltofte, CEO of Zentiva. "With GTCR's support and significant industry expertise, we believe we are ideally placed to accelerate our momentum and continue our mission of expanding access to high-quality, affordable medicines to millions of people across Europe."

"We are excited to partner with Steffen and the Zentiva team to further the Company's success," said Sean Cunningham, Managing Director and Head of Healthcare at GTCR. "As policymakers increasingly prioritize expanding access to essential medicines while ensuring long-term sustainability of healthcare systems, Zentiva plays a critical role in delivering high-quality, cost-effective therapies at scale. Combined with its differentiated geographic footprint and low-cost manufacturing capabilities, Zentiva is well positioned to strengthen its competitive advantage and deliver long-term growth and impact."